#United States #New York #class action lawsuit #Pomerantz LLP #Cytokinetics

Pomerantz Law Firm Initiation of Class Action Against Cytokinetics

Pomerantz LLP, a prominent legal firm recognized for its advocacy in securities law, has announced the initiation of a class action lawsuit against Cytokinetics, Incorporated (NASDAQ: CYTK). The lawsuit concerns allegations of securities fraud and other unlawful practices that may have negatively impacted investors. Investors who have experienced losses are urged to take immediate action, as the deadline to apply as a Lead Plaintiff is November 17, 2025.

Background of the Case

The class action represents those investors who purchased Cytokinetics' securities during a specified period in which the company's misleading practices reportedly took place. The substance of the allegations stems from Cytokinetics' failure to adequately disclose material information related to its New Drug Application (NDA) for the drug aficamten, which has raised significant concerns among investors regarding transparency and corporate governance.

On March 10, 2025, Cytokinetics revealed that the U.S. Food and Drug Administration (FDA) had opted not to hold an advisory committee meeting to evaluate the NDA for aficamten. Shortly thereafter, on May 1, 2025, in a shocking disclosure, the company acknowledged that the FDA had extended the action date for aficamten's NDA to December 26, 2025. This extension was necessary to allow the FDA to review a Risk Evaluation and Mitigation Strategy (REMS) that Cytokinetics had neglected to include in its original NDA submission.

These disclosures led to a significant drop in the company's stock price. Following the news on May 2, 2025, Cytokinetics' shares plummeted by $5.57, representing a 12.98% decline. On May 6, 2025, further damaging admissions from CEO Robert I. Blum about prior meetings with the FDA resulted in an additional stock price decline of 7.36%.

Actions for Affected Investors

Investors who purchased Cytokinetics securities during the defined class period and have incurred losses are encouraged to act quickly. To join the lawsuit, potential Lead Plaintiffs need to contact Pomerantz LLP and be prepared to provide specific information including their mailing address, telephone number, and the number of shares purchased. This information is critical for the onboarding process into the class action.

For additional details or inquiries, Danielle Peyton of Pomerantz LLP can be contacted directly via email at [email protected] or by phone at 646-581-9980, toll-free at 888.4-POMLAW (ext. 7980).

Moreover, individuals who want to review the full details of the Complaint filed can access it online through Pomerantz's official website: www.pomerantzlaw.com.

About Pomerantz LLP

Established over 85 years ago, Pomerantz LLP has gained a reputation as one of the foremost firms in corporate, securities, and antitrust class litigation. Founded by Abraham L. Pomerantz, who is often referred to as the dean of the class action bar, the firm's legacy continues as they advocate for investors and strive for justice against corporate misconduct. In its history, Pomerantz has secured numerous substantial damages awards for class members and upholds the mission of defending the rights of the wronged.

Conclusion

The ongoing developments in the Cytokinetics case serve as a reminder of the potential complexities within the pharmaceutical industry and corporate governance. For affected investors, this class action lawsuit may be a vital opportunity to seek restitution for losses incurred due to possible securities fraud. It’s essential to stay informed, proactive, and connected with legal representation to navigate this challenging landscape.